Peptides - Tesamorelin
What is Tesamorelin?
Tesamorelin is a growth hormone releasing hormone (GHRH) analog that has been shown to increase IGF-1 levels. It binds and stimulates human GHRH receptors with similar potency as endogenous GHRH. Other benefits include nootropic effects (better cognition), reducing triglycerides, decreased thickness of carotid artery walls, decreased visceral fat tissue, and decreased C-reactive protein, a marker of inflammation.
Tesamorelin was approved by the Food and Drug Administration on November 10, 2010 as a medication to induce and maintain a reduction of excess visceral fat that builds up around the liver, stomach, and other abdominal organs in HIV-infected patients. Tesamorelin is the first FDA-approved treatment for lipodystrophy (build up of visceral abdominal fat), it is a synthetic growth hormone releasing factor (GRF) that is administered in a once-daily injection.
How does it Work?
Tesamorelin stimulates the pituitary gland in the brain to secrete growth hormone. Clinical trials have shown that Tesamorelin significantly reduces abdominal fat with fewer side effects than HGH (Human Growth Hormone). Tesamorelin has also been shown to reduce lipodystrophy in HIV-infected individuals. Tesamorelin increases growth hormone release and was shown, in addition to reducing visceral fat, to improve several measures of cognitive function in both cognitively normal and mildly impaired older individuals.
Tests of executive functions and verbal memory were significantly higher in participants given Tesamorelin in a 20-week placebo-controlled trial, according to Laura D. Baker, Ph.D. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
Increases natural production of HGH (human growth hormone)
Increases IGF – 1 (insulin growth factor – 1) without altering glucose parameters
Reduces fat tissue around internal organs (i.e., visceral fat)
Reduces triglycerides (a type of fat found in your blood)
Improves cognition in adults over the age of 60